COMMUNIQUÉS West-GlobeNewswire

NeurAxis to Host Second Quarter 2024 Results and Business Update Call on Friday, August 9, 2024
05/08/2024
CARMEL, Ind., Aug. 05, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]
Dror Ortho-Design, Inc. Launches ZSMILE User Experience Trial
05/08/2024
JERUSALEM, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Dror Ortho-Design, Inc. ("Dror" or the "Company") (OTC PINK: DROR), an AI-based orthodontic platform company that has developed a proprietary solution to correct people's [...]
AFB Names 2024 Migel Medal Honorees
05/08/2024
WASHINGTON, Aug. 05, 2024 (GLOBE NEWSWIRE) -- The American Foundation for the Blind (AFB) has announced that Kim Charlson and Susan Mazrui are the winners of the Migel Medal, the highest honor in the field of blindness [...]
Merus annonce ses résultats financiers pour le deuxième trimestre 2024 et fait le point sur ses activités
03/08/2024
- Données provisoires de l’association pétosemtamab + pembrolizumab présentées lors de l’édition 2024 du congrès de l’ASCO ® , avec démonstration d’un taux de réponse solide de 67 % chez 24 patients évaluables. – [...]
NTG Nordic Transport Group acquires SCHMALZ+SCHÖN Holding GmbH
02/08/2024
Company announcement no. 6 – 24 2 August 2024 NTG Nordic Transport Group acquires SCHMALZ+SCHÖN Holding GmbH NTG Germany GmbH (“NTG”), a fully owned subsidiary of NTG Nordic Transport Group A/S, has signed an agreement [...]
FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C
02/08/2024
PDUFA Action Date for the Arimoclomol NDA is September 21, 2024 CELEBRATION, Fla., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company [...]
Avicanna Announces Changes of Auditors
02/08/2024
TORONTO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and [...]
Digicann Ventures and 3Win Corp. Sign Binding LOI for Proposed RTO Transaction
02/08/2024
/Not for distribution to U.S. news wire services or for dissemination in the United States/ VANCOUVER, British Columbia, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Digicann Ventures Ltd. (“Digicann” or the “Company”) (CSE: DCNN [...]
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
02/08/2024
Phase 2 TRANQUILITY trial is evaluating the high-sensitivity C-reactive protein (hs-CRP)-lowering effect, safety, tolerability, and pharmacokinetics (PK) of quarterly and monthly subcutaneous administration of TOUR006 [...]
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
02/08/2024
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/08/2024
SAN FRANCISCO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024
02/08/2024
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE [...]
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 juillet 2024
02/08/2024
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 juillet 2024 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/08/2024
WALTHAM, Mass. and DUBLIN, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to [...]
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
02/08/2024
ROCKAWAY, N.J., Aug. 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that on August 1, 2024, Stephen Smith [...]
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
02/08/2024
SAN DIEGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)- [...]
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02/08/2024
CAMBRIDGE, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 31, 2024, the Compensation Committee of the [...]
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/08/2024
NAARDEN, The Netherlands and MIAMI, Aug. 02, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/08/2024
WESTLAKE VILLAGE, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]

Pages